Q2 EPS Estimate for Rockwell Medical Decreased by Analyst

Rockwell Medical, Inc. (NASDAQ:RMTI) – HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Rockwell Medical in a report issued on Monday, November 25th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.01) per share for the quarter, down from their prior forecast of $0.02. HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Rockwell Medical’s current full-year earnings is ($0.03) per share. HC Wainwright also issued estimates for Rockwell Medical’s Q3 2025 earnings at ($0.01) EPS and Q4 2025 earnings at $0.01 EPS.

Several other equities research analysts have also issued reports on RMTI. RODMAN&RENSHAW upgraded shares of Rockwell Medical to a “strong-buy” rating in a research report on Thursday, November 14th. Rodman & Renshaw started coverage on shares of Rockwell Medical in a research report on Thursday, November 14th. They set a “buy” rating and a $5.00 price objective on the stock. Finally, StockNews.com lowered shares of Rockwell Medical from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st.

Rockwell Medical Stock Up 2.7 %

Shares of NASDAQ RMTI opened at $2.31 on Tuesday. The company has a current ratio of 2.41, a quick ratio of 2.00 and a debt-to-equity ratio of 0.33. The business has a 50-day moving average of $3.50 and a 200-day moving average of $2.66. The firm has a market capitalization of $74.66 million, a price-to-earnings ratio of -46.20 and a beta of 1.50. Rockwell Medical has a 12 month low of $1.16 and a 12 month high of $5.15.

Institutional Trading of Rockwell Medical

Hedge funds and other institutional investors have recently bought and sold shares of the company. Armistice Capital LLC raised its stake in shares of Rockwell Medical by 22.5% during the second quarter. Armistice Capital LLC now owns 3,221,640 shares of the company’s stock worth $5,670,000 after acquiring an additional 592,000 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Rockwell Medical by 4.0% during the 1st quarter. Vanguard Group Inc. now owns 1,118,277 shares of the company’s stock valued at $1,856,000 after purchasing an additional 43,302 shares during the last quarter. Jane Street Group LLC bought a new position in shares of Rockwell Medical during the third quarter valued at about $534,000. Walleye Capital LLC purchased a new position in shares of Rockwell Medical in the third quarter worth about $435,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Rockwell Medical by 877.1% in the 2nd quarter. Renaissance Technologies LLC now owns 102,700 shares of the company’s stock valued at $181,000 after acquiring an additional 92,189 shares during the last quarter. Hedge funds and other institutional investors own 23.31% of the company’s stock.

About Rockwell Medical

Rockwell Medical, Inc, together with its subsidiaries, operates as a healthcare company that engages in the development, manufacture, commercialization, and distribution of various hemodialysis products for dialysis providers worldwide. The company offers Triferic Dialysate and Triferic AVNU which are indicated to maintain hemoglobin in adult undergoing hemodialysis.